Seres Therapeutics (NASDAQ:MCRB) Shares Cross Above 50 Day Moving Average – Here’s What Happened

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) crossed above its 50-day moving average during trading on Wednesday . The stock has a 50-day moving average of $5.53 and traded as high as $5.60. Seres Therapeutics shares last traded at $5.54, with a volume of 63,651 shares.

Wall Street Analyst Weigh In

MCRB has been the subject of a number of recent analyst reports. HC Wainwright began coverage on shares of Seres Therapeutics in a report on Tuesday, June 23rd. They issued a “buy” rating and a $12.00 target price for the company. Weiss Ratings lowered shares of Seres Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, August 11th. Zacks Research raised shares of Seres Therapeutics to a “hold” rating in a research note on Tuesday, June 23rd. Finally, Wall Street Zen upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Seres Therapeutics presently has a consensus rating of “Hold” and an average target price of $17.00.

Seres Therapeutics Trading Up 1.4%

The firm has a market cap of $57.49 million, a PE ratio of -2.35 and a beta of 0.21. The stock’s 50 day moving average price is $5.51 and its 200 day moving average price is $7.15.

Seres Therapeutics (NASDAQ:MCRB) last released its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $0.47 EPS for the quarter, beating the consensus estimate of ($2.18) by $2.65. Seres Therapeutics had a negative return on equity of 114.82% and a negative net margin of 1,192.94%.The company had revenue of $0.74 million for the quarter, compared to analyst estimates of $0.18 million. Analysts forecast that Seres Therapeutics, Inc. will post -6.33 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Invesco Ltd. lifted its holdings in Seres Therapeutics by 37.5% in the 4th quarter. Invesco Ltd. now owns 14,360 shares of the biotechnology company’s stock worth $214,000 after buying an additional 3,918 shares in the last quarter. 683 Capital Management LLC acquired a new position in shares of Seres Therapeutics in the 4th quarter valued at approximately $778,000. ExodusPoint Capital Management LP acquired a new stake in shares of Seres Therapeutics during the fourth quarter worth approximately $190,000. OMERS ADMINISTRATION Corp acquired a new stake in shares of Seres Therapeutics during the fourth quarter worth approximately $214,000. Finally, Barclays PLC increased its stake in shares of Seres Therapeutics by 427.8% in the fourth quarter. Barclays PLC now owns 7,432 shares of the biotechnology company’s stock worth $111,000 after buying an additional 6,024 shares during the last quarter. 59.34% of the stock is owned by institutional investors and hedge funds.

About Seres Therapeutics

Seres Therapeutics is a clinical?stage microbiome therapeutics company focused on harnessing the power of the human microbiome to treat serious diseases. Headquartered in Cambridge, Massachusetts, Seres applies proprietary microbiome science and manufacturing capabilities to develop a pipeline of living microbial therapies designed to restore healthy gut function. The company’s approach leverages understanding of microbial ecology and human biology to address conditions where the native microbiome is disrupted.

Among its lead candidates is SER-109, an investigational oral microbiome therapeutic for reducing recurrence of Clostridioides difficile infection.